Pharmaceuticals Biotechnology and Life Sciences
featured
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.
» Read More
More
-
Shares of Imclone Systems fell after the company announced that phase III studies of its cancer drug Erbitux failed to meet the end point of progression free survival of non-small cell lung cancer.
-
Genentech said after markets closed Wednesday that its second-quarter profit rose 41 percent, fueled by cost-cutting and growth from its cancer drug Avastin.
-
Big contract wins and corporate dealmaking were some of the catalysts behind Monday's most actively traded stocks.
-
Warm weather and corporate announcements were some of the catalysts behind the most actively traded stocks on Friday.
-
Cramer, cut and run? Never. No matter how loud the bears growl.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Shares of the wildly popular and volatile Dendreon were treading water on unremarkable, relatively low volume for most of the day today. Then, all of a sudden, around 2:30 there was a big spike in the stock and volume surged. With less than 15 minutes left until the closing bell more than 11 million shares have been traded. The daily average recently is nearly 24 million. The shares are up more than 10%. There's still a large, but smaller (month over month) short interest in the stock.
-
The new issue market is on track for its best year since 2000.
-
Pain-free colonoscopies, PillCams and incredible growth – what’s not to like about Given Imaging?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Pfizer said after markets closed Wednesday that U.S. health regulators will approve its novel AIDS drug called maraviroc once certain conditions have been met, although the world's biggest drugmaker did not elaborate on what was necessary to obtain an outright approval.
-
Swiss drug maker Roche Holding and its Japanese partner Chugai Pharmaceutical will conduct new basic research and clinical trials on influenza drug Tamiflu, which is under strong scrutiny in Japan for a possible link to abnormal behavior.
-
We can’t all be experts at everything, which is why we have people who are experts at something. Having said that, I’ll let you in on one of my little secrets -- how to tell when a pharmaceutical story has significance. ... Also: a seemingly innocuous headline -- about Expedia -- has plenty of hidden meaning.
-
Earnings news and clinical trial data were some of the catalysts behind the most actively traded stocks on Monday.
-
If CV Therapeutics doubles, take profits. If it gets clobbered, at least the company’s best drug can treat your angina.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Analyst actions and corporate announcements were some of the catalysts behind the most actively traded stocks on Thursday.
-
Analyst actions and clinical trial data were some of the catalysts behind the most actively traded stocks on Wednesday.
-
It’s slim pickings in the sector, but there are a couple of stocks that are actually worth buying, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
If you’re dead set on cradling your drugmaker darlings, there are only a few Cramer thinks are worth owning.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Analyst actions and earnings news were some of the catalysts behind the most actively traded stocks on Tuesday. Financial stocks were in focus and Lehman Brothers rose on heavy trading volume after the investment banking firm reported strong quarterly earnings.
-
Shares of Medivation surged 26% after the company said on Monday its experimental Alzheimer's disease treatment Dimebon prevented mental deterioration in patients for a year. Neurochem said initial data was positive from a recent study of its Alzheimer's disease treatment Alzhemed.